28,903 Shares in ProQR Therapeutics (NASDAQ:PRQR) Acquired by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. acquired a new position in ProQR Therapeutics (NASDAQ:PRQR) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 28,903 shares of the biopharmaceutical company’s stock, valued at approximately $77,000.

Several other large investors have also recently added to or reduced their stakes in the business. BNP Paribas Financial Markets lifted its stake in shares of ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 7,300 shares during the period. Ballentine Partners LLC acquired a new position in ProQR Therapeutics during the fourth quarter worth about $61,000. M&T Bank Corp bought a new stake in ProQR Therapeutics in the fourth quarter worth about $330,000. Finally, Raymond James Financial Inc. acquired a new stake in ProQR Therapeutics in the 4th quarter valued at about $260,000. 32.65% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Citigroup raised ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price target on the stock in a report on Monday, March 10th. Oppenheimer assumed coverage on ProQR Therapeutics in a research report on Friday, January 10th. They set an “outperform” rating and a $15.00 target price on the stock. JMP Securities reiterated a “market outperform” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a research report on Thursday, December 12th. StockNews.com cut ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Finally, HC Wainwright upped their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, March 14th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, ProQR Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $9.50.

ProQR Therapeutics Stock Performance

NASDAQ:PRQR opened at $1.61 on Wednesday. The company has a market capitalization of $169.39 million, a P/E ratio of -5.03 and a beta of 0.24. The stock’s 50 day moving average price is $2.13 and its 200 day moving average price is $2.61. ProQR Therapeutics has a 52 week low of $1.59 and a 52 week high of $4.62.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).